T0901317 NLT 98%

T0901317 is a potent and selective agonist for LXR and FXR, with EC₅₀s of 50 nM and 5 μM, respectively^[1,2]. T0901317 induces its anti-proliferative and cytotoxic effects via an LXR-independent mechanism. T0901317 significantly suppresses cell proliferation and induces programmed cell death in a dose- and time-dependent manner^[3]. T0901317 can protect mice from high fat diet-induced obesity and insulin resistance^[4]. IC50 & Target: FXR, LXR^[1,2] In Vitro: T0901317 (5-50 μM; 72 hours) significantly inhibits cellular proliferation in all cell lines in a dose-dependent and time-dependent manner^[3].
T0901317 (10 μM; 24-72 hours) decreases the percentage of cells in S phase and increases the percentage of cells in the G0/G1 phase, indicating a cell cycle arrest at the G1-S checkpoint. The percentage of cells in G0/G1 phase increases in a time-dependent manner^[3].
T0901317 (10-40 μM; 24 hours ) results in a significant increase of cells in early apoptosis^[3].
T0901317 (5-40 μM; 48 hours) results in an increase of p21 and p27 protein expression in a dose-dependent manner after 48 hours^[3].
In Vivo: T0901317 (i.p.; 50 mg/kg; twice weekly for 7 days) significantly slowes down the weight gain of C57/BL6 mice^[4] .